BTX-A51
As of the edition of 20 October 2026, BTX-A51 is a small molecule: in active development; acts on CDK9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CDK9 | Cyclin-dependent kinase 9 | P50750 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 3 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Edgewood Oncology | Lead sponsor of trials | 2020 to now |